Psoriasis: a review. II.
Notwithstanding the intense interest in systemic cytotoxic therapy in recent years, the great majority in psoriatics are likely to go on needing topical therapy with tar, dithranol or corticosteroids, and a welcome trend is the spreading of interest in day care centres such as those in Paris (GRUPPER), Stockholm (THYRESSON), Stanford (FARBER) and San Francisco (CRAM) evolving from the out-patient regimes advocated by INGRAM in Leeds a generation ago.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000875:Anthralin / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001380:Azauridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008130:Lomustine / Q000627:therapeutic use; D008466:Mechlorethamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy / Q000628:therapy*; D013638:Tars / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use; D014467:Ultraviolet Therapy
D000305:Adrenal Cortex Hormones; D013638:Tars; D008466:Mechlorethamine; D014212:Tretinoin; D008130:Lomustine; D001380:Azauridine; D001379:Azathioprine; D005472:Fluorouracil; D000875:Anthralin; D006918:Hydroxyurea; D008727:Methotrexate